tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2023-101-4-87-93tiblj-1738Research ArticleОБЗОРREVIEWГенетические аспекты лекарственной устойчивости микобактерий туберкулеза к новым препаратам с противотуберкулезной активностьюGenetic Aspects of Mycobacterium Tuberculosis Resistance to New Anti-Tuberculosis DrugsКукурикаА. В.KukurikaA. V.

Кукурика Анастасия Владимировна - специалист центра социально значимых инфекций.

127473, Москва, ул. Достоевского, д. 4

Тел.: +7 (495) 681-11-66

Anastasia V. Kukurika - Specialist of Center of Socially Important Infections.

4, Dostoevsky St., Moscow, 127473

Phone: +7 (495) 681-11-66

nastya_kukurika@mail.ruВеселоваЕ. И.VeselovaE. I.

Веселова Елена Игоревна - кандидат медицинских наук, научный сотрудник научного отдела инфекционной патологии.

127473, Москва, ул. Достоевского, д. 4

Тел.: +7 (495) 681-11-66

Elena I. Veselova - Candidate of Medical Sciences, Researcher of Infectious Pathology Research Department.

4, Dostoevsky St., Moscow, 127473

Phone: +7 (495) 681-11-66

drveselovae@mail.ruПерегудоваА. Б.PeregudovaA. B.

Перегудова Алла Борисовна – кандидат медицинских наук, заведующая инфекционным отделением.

127473, Москва, ул. Достоевского, д. 4

Тел.: +7 (495) 681-11-66

Alla B. Peregudova - Candidate of Medical Sciences, Head of Infectious Diseases Department.

4, Dostoevsky St., Moscow, 127473

Phone: +7 (495) 681-11-66

PeregudovaAB@nmrc.ruФГБУ «Научный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthRussian Federation20232808202310148793Copyright © Кукурика А.В., Веселова Е.И., Перегудова А.Б., 20232023Кукурика А.В., Веселова Е.И., Перегудова А.Б.Kukurika A.V., Veselova E.I., Peregudova A.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1738

Проанализированы 57 публикаций, посвященных изучению генетических механизмов формирования лекарственной устойчивости микобактерий туберкулеза к бедаквилину, деламаниду, претоманиду, линезолиду и клофазимину. Выявление генетических факторов лекарственной устойчивости МБТ - основа поиска новых мишеней при создании противотуберкулезных препаратов и разработки методов тестирования лекарственной чувствительности.

We analyzed 57 publications devoted to study of genetic mechanisms of formation of drug resistance of Mycobacterium tuberculosis to bedaquiline, delamanid, pretomanid, linezolid, and clofazimine. Identification of genetic factors of MTB drug resistance make the basis to search for new targets in development of anti-tuberculosis drugs and methods for drug susceptibility testing.

лекарственная устойчивостьмикобактерия туберкулезапротивотуберкулезные препаратымутацииdrug resistancemycobacterium tuberculosisanti-tuberculosis drugsmutationsReferencesВасильева И. А., Самойлова А. Г., Зимина В. Н., Ловачева О. В., Абрамченко А.В. Химиотерапия туберкулеза в России - история продолжается // Туберкулёз и болезни лёгких. - 2023. - Т. 101, № 2. - С. 8-12. https://doi.org/10.58838/2075-1230-2023-101-2-8-12Vasilyeva I. A., Samoylova A. G., Zimina V. N., Lovacheva O. V., Abramchenko A. V. Chemotherapy for tuberculosis in Russia - the story continues. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 2, pp. 8-12. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-2-8-12Гайда А. И., Абрамченко А. В., Романова М. И., Тоичкина Т. В., Бурыхин В. С., Борисов С. Е., Филиппов А. В., Кузнецова Т. А., Перхин Д. В., Свешникова О. М., Лехляйдер М. В., Пантелеев А. М., Тоинова С. В., Масленникова Т. И., Галахова Д. О., Популяшина Л. Н., Саенко Г. И., Анисимова Е. С., Свичарская А. К., Сосова Н. А., Ловачева О. В., Марьяндышев А. О., Самойлова А. Г. Обоснование длительности химиотерапии больных туберкулезом с множественной и преширокой лекарственной устойчивостью возбудителя в Российской Федерации // Туберкулёз и болезни лёгких. - 2022. Т. 100, № 12. - С. 44-53. https://doi.org/10.21292/2075-1230-2022-100-12-44-53Gayda A. I., Abramchenko A. V., Romanova M. I., Toichkina T. V., Burykhin V. S., Borisov S. E., Filippov A. V., Kuznetsova T. A., Perkhin D. V., Sveshnikova O. M., Lekhleyder M. V., Panteleev A. M., Toinova S. V., Maslennikova T. I., Galakhova D. O., Populyashina L. N., Saenko G. I., Anisimova E. S., Svicharskaya A. K., Sosova N. A., Lovacheva O. V., Maryandyshev A. O., Samoylova A. G. Substantiation of duration of chemotherapy in tuberculosis patients with multiple and pre-extensive drug resistance in the Russian Federation. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 12, pp. 44-53. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-12-44-53Almeida D., Ioerger T., Tyagi S. et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis // Antimicrob Agents Chemother. - 2016. - № 60. - Р. 4590-9.Almeida D., Ioerger T., Tyagi S., et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2016, no. 60, pp. 4590-9.Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L., Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L. et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline // PLoS One. - 2014. - № 9. Р. e102135.Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L., Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L. et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One, 2014, no. 9, pp. e102135.Battaglia S., Spitaleri A., Cabibbe A. M., Meehan C. J., Utpatel C., Ismail N., Tahseen S., Skrahina A., Alikhanova N., Mostofa Kamal S.M., Barbova A., Niemann S., Groenheit R., Dean A. S., Zignol M., Rigouts L., Cirillo D. M. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. J. Clin. Microbiol., 2020, vol. 58, no. 11, pp. e01304-20.Battaglia S., Spitaleri A., Cabibbe A. M., Meehan C. J., Utpatel C., Ismail N., Tahseen S., Skrahina A., Alikhanova N., Mostofa Kamal S. M., Barbova A., Niemann S., Groenheit R., Dean A. S., Zignol M., Rigouts L., Cirillo D. M. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains // J. Clin. Microbiol. // 2020. - Vol. 58, № 11. - Р. e01304-20.Beckert P., Hillemann D., Kohl T. A. et al. RplC T460C identified as a dominant mutation in linezolid-resistantMycobacteriumtuberculosis strains. Antimicrob. Agents Chemother., 2012, no. 56, pp. 2743-5.Beckert P., Hillemann D., Kohl T. A. et al. RplC T460C identified as a dominant mutation in linezolid-resistantMycobacteriumtuberculosis strains // Antimicrob Agents Chemother. - 2012. - № 56. - Р. 2743-5.Castro R. A. D., Borrell S., Gagneux S. The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis. FEMS Microbiology Reviews, 2020, fuaa 071, pp. 1-27.Castro R. A. D., Borrell S., Gagneux S. The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis // FEMS Microbiology Reviews. - 2020. - fuaa 071. - Р. 1-27.Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva, World Health Organization, 2021.Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021.De Vos M., Ley S., Derendinger B., Dippenaar A., Grobbelaar M., Reuter A., et al. Emergence of bedaquiline resistance after completion of bedaquiline-based drug resistant TB treatment: a case study from South Africa. Russ. J. Infect. Immun., 2018, no. 8, pp. 566.De Vos M., Ley S., Derendinger B., Dippenaar A., Grobbelaar M., Reuter A. et al. Emergence of bedaquiline resistance after completion of bedaquiline-based drug resistant TB treatment: a case study from South Africa // Russ J Infect Immun. - 2018. - № 8. - Р. 566.Dookie N., Rambaran S., Padayatchi N., Mahomed S., Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J. Antimicrob. Chemother., 2018, vol. 73, pp. 1138-1151.Dookie N., Rambaran S., Padayatchi N., Mahomed S., Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care // J. Antimicrob. Chemother. - 2018, Vol. 73. - P. 1138-1151.Feuerriegel S., Köser C. U., Bau D., Rusch-Gerdes S., Summers D. K., Archer J. A., Marti-Renom M. A., Niemann S. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob. Agents Chemother., 2011, no. 55, pp. 5718-5722.Feuerriegel S., Köser C. U., Bau D., Rusch-Gerdes S., Summers D. K., Archer J. A., Marti-Renom M. A., Niemann S. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824 // Antimicrob. Agents Chemother. - 2011 - № 55. - Р. 5718-5722.Ghajavand H., Kamakoli M. K., Khanipour S., Dizaji P. S., Masoumi M., Jamnani R. F., Fateh A., Siadat S. D., Vaziri F. High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness. Antimicrob. Agents Chemother., 2019, no. 63, pp. e02530-18.Ghajavand H., Kamakoli M. K., Khanipour S., Dizaji P. S., Masoumi M., Jamnani R. F., Fateh A., Siadat S. D., Vaziri F. High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness // Antimicrob. Agents Chemother. - 2019. - № 63. - Р. e02530-18.Ghodousi A., Rizvi A. H., Baloch A. Q., Ghafoor A., Khanzada F. M., Qadir M., Borroni E., Trovato A., Tahseen S., Cirillo D. M. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Antimicrobial. Agents Chemother., 2019, no. 63, pp. e00915-19.Ghodousi A., Rizvi A. H., Baloch A. Q., Ghafoor A., Khanzada F. M., Qadir M., Borroni E., Trovato A., Tahseen S., Cirillo D. M. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan // Antimicrobial. Agents Chemother. - 2019. - № 63. - Р. e00915-19.Hartkoorn R. C., Uplekar S., Cole S. T. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, no. 58, pp. 2979-81.Hartkoorn R. C., Uplekar S., Cole S. T. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2014. - № 58. - Р. 2979-81.Haver H. L., Chua A., Ghode P. et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2015, no. 59, pp. 5316-23.Haver H. L., Chua A., Ghode P. et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2015. - № 59. - Р. 5316-23.Hoffmann H., Kohl T. A., Hofmann-Thiel S., et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. Am. J. Respir. Crit. Care Med., 2016, no. 193, pp. 337-40.Hoffmann H., Kohl T. A., Hofmann-Thiel S. et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee // Am J. Respir. Crit. CareMed // 2016. - № 193. - P. 337-40.Hu M., Fu L., Wang B., Xu J., Guo S., Zhao J., Li Y., Chen X., Lu Y. Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro. Infect. Drug Resist., 2020, no. 13, pp. 1751-176.Hu M., Fu L., Wang B., Xu J., Guo S., Zhao J., Li Y., Chen X., Lu Y. Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro // Infect Drug Resist. - 2020. - № 13. - Р. 1751-1761.Ismail N., Ismail N. A., Omar S. V., Peters R. P. H. Study of Stepwise Acquisition of of rv0678 and atpE Mutations Conferring Bedaquiline Resistance. Antimicrob. Agents Chemother., 2019, no. 63, pp. e00292-19.Ismail N., Ismail N. A., Omar S. V., Peters R. P. H. Study of Stepwise Acquisition of of rv0678 and atpE Mutations Conferring Bedaquiline Resistance // Antimicrob. Agents Chemother. - 2019. - № 63. - Р. e00292-19.Ismail N., Omar S. V., Ismail N. A., Peters R. P. H. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data in Brief, 2018, vol. 20, pp. 1975-1983.Ismail N., Omar S. V., Ismail N. A., Peters R. P. H. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis // Data in Brief. - 2018. - Vol. 20. - P. 1975-1983.Ismail N., Omar S. V., Ismail N. A., Peters R. P. H. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. J. Microbiol. Methods, 2018, no. 153, pp. 1-9.Ismail N., Omar S. V., Ismail N. A., Peters R. P. H. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants // J. Microbiol. Methods. - 2018. - № 153. - Р. 1-9.Ismail N., Omar S. V., Joseph L., Govender N., Blows L., Ismail F., Koornhof H., Dreyer A. W., Kaniga K., Ndjeka N. Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective Cohort study. EBioMedicine, 2018, no. 28, pp. 136-142.Ismail N., Omar S. V., Joseph L., Govender N., Blows L., Ismail F., Koornhof H., Dreyer A. W., Kaniga K., Ndjeka N. Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective Cohort study // EBioMedicine. - 2018. - № 28. - Р. 136-142.Ismail N., Peters R. P. H., Ismail N. A., et al. Clofazimine exposure in vitro selects efflux pump mutants and bedaquiline resistance. Antimicrob. Agents Chemother., 2019, no. 63, pp. e02141-18.Ismail N., Peters R. P. H., Ismail N. A., et al. Clofazimine exposure in vitro selects efflux pump mutants and bedaquiline resistance // Antimicrob. Agents Chemother. - 2019. - № 63. - Р. e02141-18.Kabahita J. M., Kabugo J., Kakooza F., Adam I., Guido O., Byabajungu H., Namutebi J., Namaganda M. M., Lutaaya P., Otim J., Kakembo F. E., Kanyerezi S., Nabisubi P., Sserwadda I., Kasule G.W., Nakato H., Musisi K., Oola D., Joloba M. L., Mboowa G. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda // Antimicrob. Resist. Infect. Control. - 2022. - Vol. 11, № 1. - Р. 68. https://doi.org/10.1186/s13756-022-01101-2Kabahita J. M., Kabugo J., Kakooza F., Adam I., Guido O., Byabajungu H., Namutebi J., Namaganda M. M., Lutaaya P., Otim J., Kakembo F. E., Kanyerezi S., Nabisubi P., Sserwadda I., Kasule G. W., Nakato H., Musisi K., Oola D., Joloba M. L., Mboowa G. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. Antimicrob. Resist. Infect. Control, 2022, vol. 11, no. 1, pp. 68. https://doi.org/10.1186/s13756-022-01101-2Kadura S., King N., Nakhoul M., Zhu H., Theron G., Köser C. U., Farhat M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid // J. Antimicrob. Chemother. - 2020. - Vol. 75. - P. 2031-2043.Kadura S., King N., Nakhoul M., Zhu H., Theron G., Köser C. U., Farhat M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J. Antimicrob. Chemother., 2020, vol. 75, pp. 2031-2043.Kaniga K., Hasan R., Jou R., Vasiliauskienė E., Chuchottaworn C., Ismail N., Metchock B., Miliauskas S., Viet Nhung N., Rodrigues C., Shin S., Simsek H., Smithtikarn S., Ngoc ALT, Boonyasopun J., Kazi M., Kim S., Kamolwat P., Musteikiene G., Sacopon C. A., Tahseen S., Vasiliauskaite L., Wu M. H., Vally Omar S. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates // J. Clin. Microbiol. - 2022. - Vol. 60. - № 1. - Р. e0291920. https://doi.org/10.1128/JCM.02919-20Kaniga K., Hasan R., Jou R., Vasiliauskienė E., Chuchottaworn C., Ismail N., Metchock B., Miliauskas S., Viet Nhung N., Rodrigues C., Shin S., Simsek H., Smithtikarn S., Ngoc A. L. T., Boonyasopun J., Kazi M., Kim S., Kamolwat P., Musteikiene G., Sacopon C. A., Tahseen S., Vasiliauskaite L., Wu M. H., Vally Omar S. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J. Clin. Microbiol., 2022, vol. 60, no. 1, pp. e0291920. https://doi.org/10.1128/JCM.02919-20Karmakar M., Rodrigues C. H. M., Holt K. E., Dunstan S. J., Denholm J., Ascher D. B. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE // PLoS ONE. - 2019. - № 14. - Р. e0217169.Karmakar M., Rodrigues C. H. M., Holt K. E., Dunstan S. J., Denholm J., Ascher D. B. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. PLoS ONE, 2019, no. 14, pp. e0217169.Köser C. U., Maurer F. P., Kranzer K. ‘Those who cannot remember the past are condemned to repeat it': drug-susceptibility testing for bedaquiline and delamanid // Int. J. Infect. Dis. - 2019. - 80S. - S32-S35.Köser C. U., Maurer F. P., Kranzer K. ‘Those who cannot remember the past are condemned to repeat it': drug-susceptibility testing for bedaquiline and delamanid. Int. J. Infect. Dis., 2019, 80S, S32-S35.Lee B. M., Harold L. K., Almeida D. V., Afriat-Jurnou L., Aung H. L., Forde B. M., Hards K., Pidot S. J., Ahmed F. H., Mohamed A. E., Taylor M. C., West N. P., Stinear T. P., Greening C., Beatson S. A., Nuermberger E. L., Cook G. M., Jackson C. J. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering // PLoS Pathog. - 2020. - № 16. - Р. e1008287.Lee B. M., Harold L. K., Almeida D. V., Afriat-Jurnou L., Aung H. L., Forde B. M., Hards K., Pidot S. J., Ahmed F. H., Mohamed A. E., Taylor M. C., West N. P., Stinear T. P., Greening C., Beatson S. A., Nuermberger E. L., Cook G. M., Jackson C. J. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. PLoS Pathog., 2020, no. 16, pp. e1008287.Liu Y., Gao J., Du J., Shu W., Wang L., Wang Yu., Xue Z. , Li L., Xu S., Pang Yu. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis // Int. J. of Inf. Diseases. - 2021. - Vol. 102 - P. 392-3.Liu Y., Gao J., Du J., Shu W., Wang L., Wang Yu., Xue Z., Li L., Xu S., Pang Yu. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int. J. of Inf. Diseases, 2021, vol. 102, pp. 392-3.Makafe G. G., Cao Y., Tan Y. et al. Role of the Cys154Arg substitution in ribosomal protein L3 in oxazolidinone resistance in Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. - 2016. - № 60. - Р. 3202-6.Makafe G. G., Cao Y., Tan Y. et al. Role of the Cys154Arg substitution in ribosomal protein L3 in oxazolidinone resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2016, no. 60, pp. 3202-6.Manjunatha U. H., Boshoff H., Dowd C. S. et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacteriumtuberculosis // Proc. Natl. Acad. Sci USA. - 2006. - № 103. - Р. 431-6.Manjunatha U. H., Boshoff H., Dowd C. S. et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacteriumtuberculosis. Proc. Natl. Acad. Sci. USA, 2006, no. 103, pp. 431-6.Mansjö M., Karlsson Lindsjö O., Grönfors Seeth C., Groenheit R., Werngren J. The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. - 2022. - Vol. 66, № 12. - Р. e0102622. https://doi.org/10.1128/aac.01026-22Mansjö M., Karlsson Lindsjö O., Grönfors Seeth C., Groenheit R., Werngren J. The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2022, vol. 66, no. 12, pp. e0102622. https://doi.org/10.1128/aac.01026-22Martinez E., Hennessy D., Jelfs P., Crighton T., Chen S. C. A., Sintchenko V. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia // Tuberculosis. - 2018. - № 111. - Р. 31-34.Martinez E., Hennessy D., Jelfs P., Crighton T., Chen S. C. A., Sintchenko V. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia. Tuberculosis, 2018, no. 111, pp. 31-34.McNeil M. B., Dennison D. D., Shelton C. D. et al. In vitro isolation and characterization of oxazolidinone-resistant Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. - 2017. - № 61. - Р. e01296-17.McNeil M. B., Dennison D. D., Shelton C. D. et al. In vitro isolation and characterization of oxazolidinone-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2017, no. 16, pp. e01296-17.Merker M., Kohl T. A., Barilar I. et al. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex // Genome Med. - 2020. - № 12. - Р. 27.Merker M., Kohl T. A., Barilar I. et al. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med., 2020, no. 12, pp. 27.Mokrousov I., Akhmedova G., Polev D., Molchanov V., Vyazovaya A. Acquisition of bedaquiline resistance by extensively drug-resistant Mycobacterium tuberculosis strain of Central Asian Outbreak clade // Clinical Microbiology and Infection. - 2019. - Vol. 25. - P. 1295-1297.Mokrousov I., Akhmedova G., Polev D., Molchanov V., Vyazovaya A. Acquisition of bedaquiline resistance by extensively drug-resistant Mycobacterium tuberculosis strain of Central Asian Outbreak clade. Clinical Microbiology and Infection, 2019, vol. 25, pp. 1295-1297.Omar S. V., Joseph L., Said H. M. et al. Whole genome sequencing for drug resistance determination in Mycobacterium tuberculosis // Afr. J. Lab. Med. - 2019. - Vol. 8, № 1. - P. a801.Omar S. V., Joseph L., Said H. M. et al. Whole genome sequencing for drug resistance determination in Mycobacterium tuberculosis. Afr. J. Lab. Med., 2019, vol. 8, no. 1, pp. a801.Pang Y., Zong Z., Huo F. et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China // Antimicrob. Agents. Chemother. - 2017. - № 61. - Р. e00900-17.Pang Y., Zong Z., Huo F. et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob. Agents Chemother., 2017, no. 61, pp. e00900-17.Park S., Jung J., Kim J., Han S. B., Ryoo S. Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates // J. Clin. Med. - 2022. - Vol. 11, № 7. - Р. 1927. https://doi.org/10.3390/jcm11071927Park S., Jung J., Kim J., Han S. B., Ryoo S. Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates. J. Clin. Med., 2022, vol. 11, no. 7, pp. 1927. https://doi.org/10.3390/jcm11071927Ramirez N., Vargas Q., Diaz G. Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid // Antibiotics. - 2020. - Vol. 9. - P. 133.Ramirez N., Vargas Q., Diaz G. Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid. Antibiotics, 2020, vol. 9, pp. 133.Reichmuth M. L., Homke R., Zurcher K., Sander P., Avihingsanon A., Collantes J., Loiseau C., Borrell S., Reinhard M., Wilkinson R. J., Yotebieng M., Fenner L., Bottger E. C., Gagneux S., Egger M., Keller P. M., on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA). Natural polymorphisms in Mycobacterium tuberculosis conferring resistance to delamanid in drugnaive patients // Antimicrob. Agents. Chemother. - 2020. - № 64.- Р. 00513-20.Reichmuth M. L., Homke R., Zurcher K., Sander P., Avihingsanon A., Collantes J., Loiseau C., Borrell S., Reinhard M., Wilkinson R.J., Yotebieng M., Fenner L., Bottger E. C., Gagneux S., Egger M., Keller P. M., on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA). Natural polymorphisms in Mycobacterium tuberculosis conferring resistance to delamanid in drugnaive patients. Antimicrob. Agents Chemother., 2020, no. 64, pp. 00513-20.Richter E., Rüsch-Gerdes S., Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. - 2007. - № 51. - Р. 1534-6.Richter E., Rüsch-Gerdes S., Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2007, no. 51. pp. 1534-6.Rifat D., Li S-Y., Ioerger T, Lanoix J.-P., Lee J., Bashiri G., Sacchettini J., Nuermberger E. Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in Mycobacterium tuberculosis. - bioRxiv, 2018.Rifat D., Li S-Y., Ioerger T, Lanoix J.-P., Lee J., Bashiri G., Sacchettini J., Nuermberger E. Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in Mycobacterium tuberculosis. bioRxiv, 2018.Rifat D., Li S. Y., Ioerger T., Shah K., Lanoix J. P., Lee J., Bashiri G., Sacchettini J., Nuermberger E. Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. - 2020. - Vol. 65, № 1. - P. e01948-20.Rifat D., Li S. Y., Ioerger T., Shah K., Lanoix J. P., Lee J., Bashiri G., Sacchettini J., Nuermberger E. Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2020, vol. 65, no. 1, pp. e01948-20.Schena E., Nedialkova L., Borroni E., Battaglia S., Cabibbe A. M., Niemann S., et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtiter assay and the BACTECTM MGITTM 960 system // J. Antimicrob. Chemother. - 2016. - № 71. - Р. 1532-9.Schena E., Nedialkova L., Borroni E., Battaglia S., Cabibbe A. M., Niemann S. et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtiter assay and the BACTECTM MGITTM 960 system. J. Antimicrob. Chemother., 2016, no. 71, pp. 1532-9.Somoskovi A., Bruderer V., Homke R. et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment // Eur. Respir. J. - 2015. - № 45. - Р. 554-7.Somoskovi A., Bruderer V., Homke R. et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur. Respir. J., 2015, no. 45, pp. 554-7.Swain S. S., Sharma D., Hussain T., Pati S. Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis // Emerging Microbes & Infections. - 2020. - Vol. 9, № 1. - P. 1651-1663.Swain S. S., Sharma D., Hussain T., Pati S. Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis. Emerging Microbes & Infections, 2020, vol. 9, no. 1, pp. 1651-1663.Tiberi S., Cabibbe A. M., Tomlins J., Cirillo D. M., Migliori G. B. Bedaquiline Phenotypic and Genotypic Susceptibility Testing,Work in Progress! // EBioMedicine. - 2018. - № 29. - Р. 11-12.Tiberi S., Cabibbe A. M., Tomlins J., Cirillo D. M., Migliori G. B. Bedaquiline Phenotypic and Genotypic Susceptibility Testing,Work in Progress! EBioMedicine, 2018, no. 29, pp. 11-12.Veziris N., Bernard C., Guglielmetti L. et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors // Eur. Respir. J. - 2017. - № 49. - Р. 1601719.Veziris N., Bernard C., Guglielmetti L. et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur. Respir. J., 2017, no. 49, pp. 1601719.Villellas C., Coeck N., Meehan C. J. et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline // J. Antimicrob. Chemother. - 2017. - № 72. - Р. 684-90.Villellas C., Coeck N., Meehan C. J. et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J. Antimicrob. Chemother., 2017, no. 72, pp. 684-90.Walker T. M., Miotto P., Koser C. U., Fowler P. W., Knaggs J., Iqbal Z., Hunt M., Chindelevitch L., Farhat M., Cirillo D. M., Comas I., Posey J., Omar S. V., Peto T. E., Suresh A., Uplekar S., Laurent S., Colman R. E., Nathanson C. M., Zignol M., Walker A. S.; CRyPTIC Consortium; Seq&Treat Consortium; Crook D. W., Ismail N., Rodwell T. C. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis // Lancet Microbe. -2022. - Vol. 3, № 4. - Р. e265-e273. https://doi.org/10.1016/S2666-5247(21)00301-3Walker T. M., Miotto P., Koser C. U., Fowler P. W., Knaggs J., Iqbal Z., Hunt M., Chindelevitch L., Farhat M., Cirillo D. M., Comas I., Posey J., Omar S. V., Peto T. E., Suresh A., Uplekar S., Laurent S., Colman R. E., Nathanson C. M., Zignol M., Walker A.S.; CRyPTIC Consortium; Seq&Treat Consortium; Crook D. W., Ismail N., Rodwell T. C. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis. Lancet Microbe, 2022, vol. 3, no. 4, pp. e265-e273. https://doi.org/10.1016/S2666-5247(21)00301-3Xu J., Wang B., Hu M. et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis // Antimicrob. Agents. Chemother. - 2017. - 61. - Р. e00239-17.Xu J., Wang B., Hu M. et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother., 2017, 61, pp. e00239-17.Yang J. S., Kim K. J., Choi H., Lee S. H. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea // Ann. Lab. Med. - 2018. - Vol. 38. - P. 563-568.Yang J. S., Kim K. J., Choi H., Lee S. H. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Ann. Lab. Med., 2018, vol. 38, pp. 563-568.Zhang S., Chen J., Cui P. et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis // J. Antimicrob. Chemother. - 2015. - № 70. - Р. 2507-10.Zhang S., Chen J., Cui P. et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother., 2015, no. 70, pp. 2507-10.Zhang S., Chen J., Cui P. et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid // Antimicrob. Agents. Chemother. - 2016. - № 60. - Р. 2542-4.Zhang S., Chen J., Cui P. et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob. Agents Chemother., 2016, no. 60, pp. 2542-4.Zhang Z., Pang Y., Wang Y. et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrugresistant and extensively drug-resistant tuberculosis in China // Int. J. Antimicrob. Agents. - 2014. - № 43. - Р. 231-5.Zhang Z., Pang Y., Wang Y. et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrugresistant and extensively drug-resistant tuberculosis in China. Int. J. Antimicrob. Agents, 2014, no. 43, pp. 231-5.Zimenkov D. V., Nosova E. Y., Kulagina E. V. et al. Examination of bedaquiline and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region // J. Antimicrob. Chemother. - 2017. - № 72. - Р. 1901-6.Zimenkov D. V., Nosova E. Y., Kulagina E. V. et al. Examination of bedaquiline and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J. Antimicrob. Chemother., 2017, no. 72, pp. 1901-6.

The authors declare that there are no conflicts of interest present.